PDFファイル
Contents
1. Lemon PSA EET R1 2 10 C 12 R2 2 8 C 12 R1 37200 sd X J 2 PSA B x2 R2 81906 130mLx4 A16792 1 950mLx4 R3 XEURI S0 S5 PSA lt 37205 2 5 mL 37206 ded PSA 14mLx1 A79784 Dxl WB 32 9mL x 2 AON 20 21 Lilja H et al National Academy of Clinical2. 1 PSA REL ER 50 85 Zell JU USE 28 2 25 L PSA Access
3. 2 2 10C 15 30 18 R1 2 10 C 28 R2 14 2 R3 i 15 30 C S0 S5 2 10C 3 37209 81901 386167 4
4. 1 4 ng mL n 6 374 PSA 2 1 S5 S5 PSA 1 4 1 9 Dxl 800 600 Dxl WB 1 9 2 Dxl 800 600
5. JDA Access Access2 Synchron LXi725 UniCel Dx 800 600 0 1 R1 Ria PSA im PSA PPD 4 4 3 R2 ERE Mtn 1 2 3 2 2 R3 S0 S1 S2
6. 3 3 5 ProClin 300 2 1 2 3 4 Lc 3 o 6 2
7. PSA 6 5a reductase inhibitor PSA PSA 7 PSA WHO96 670 PSA 4 ng mL WHO96 670 20 3 1 ng mL
8. PER PSA 24 2 8 C 5 20C 5 70 C 363738 5 free PSA total PSA 1 25L Dxl 800 600 1 I 50 L ng mL 1
9. 15 2 0 5 1 5ng mL 15 10 20ng mL 159 3 CV 7 0 008 150ng mL 334 0 9927 Y 1 03X 0 21 X Tandem R 1 1 HIV HBV HCV
10. 127 5ng mL 3 50 000 ng mL hook 4 HAMA 8 5 PSA PSA PSA DRE DRE PSA
11. PSA 1990 PSA 9092PSA ACT 10 free PSA PSA non equimolar WHO 1 IS 96 670 PSA WHO96 670 WHO96 670 20 PSA 4 0 ng mL WHO96 970 3 1 ng mL 62725293051 32 34 42 5 1 60 110ng mL
12. prostate specific antigen PSA 3438 7 8 9 10 11 12 13 14 PSA 1979 Wang 34 000Da PSA 3 1 w PSA 2 w antichymotrypsin ACT PSA ACT 719 3 PSA free PSA 161718 2 PSA ACT free PSA PSA total PSA PSA ACT free PSA 9
13. PSA 0 5 2 0 10 75 Sasa eonun S5 RARIOR PSA PSA PSA PSA PSA PPD PPD i PSA PSA 1 2 1 8 nep PSA f EI f FH S n8 E 3
14. UniCel Dxl 800 4max 540nm PSA 20 5 PSA 2 1 1
15. 20mg dL 2 500mg dL 3 1 500mg dL PSA DRE TRUS PSA PSA PSA PSA 6 PSA 1 co
16. free PSA total PSA 5509 2 PSA 1990 99 Equimolar free PSA PSA ACT skewed non equimolar free PSA equimolar PSA free PSA PSA ACT PSA PSA PSA
17. 2013 11 2 e 12 1 20500AMY00118000 37200 aa COULTER PSA eddie PSA PSA WHO 96 670
18. 6 584 9 32 D Amico AV Whittington R Malkowicz SB Schultz D Blank K Broderick GA et al Biochemical outcome after radical prostatectomy external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 969 1998 DHHS NIOSH Publication No 78 127 August 1976 Current Intelligence Bulletin 13 Explosive Azide Hazard Available http www cdc gov niosh Ornstein DK Rao GS Smith DS Ratliff TL Basler JW Catalona WJ Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels J Urol 1997 157 195 198 Yuan JJ Coplen DE Petros JA Figenshau RS Ratliff TL Smith DS Catalona WJ Effects of rectal examination prostatic massage ultrasonography and needle biopsy on serum prostate specific antigen levels J Urol 1992 147 810 814 Woodrum DL French C Shamel LB Stability of free PSA in serum samples under a variety of sample collection and sample storage conditions Urology 1996 48 Suppl 33 39 Woodrum DL French CF Hill TM Roman SJ Slatore HL Shaffer JL York LG Eure KL Loveland KG Gasior GH Southwick PC Shamel LB Analytical performance of the Tandem R free PSA immuno assay measuring free prostate specific antigen Clin Chem 1997 43 1203 1208 Woodrum DL York L Two year stability of free and total PSA in frozen serum samples Urology 1998 52 247 251 Cembrowski GS Carey RN Laboratory Quality Manag
19. Biochemistry Laboratory Medicine Practice Guidelines LMPG Practice Guidelines and Recommendations for Use of Tumor Markers in the Clinic Prostate Cancer Section B Draft 2006 National Academy of Clinical Biochemistry Cancer Facts and Figures 1994 American Cancer Society Inc 1994 1 28 Walsh PC Why make an early diagnosis of prostate cancer J Urol 1992 147 853 854 Catalona WJ Smith DS Ratliff TL Dodds KM Coplen DE Yuan JJ Petros JA Andriole GL Measurement of prostate specific antigen in serum as a screening test for prostate cancer New Engl J Med 1991 324 1156 1161 Mettlin C Lee F Drago J Murphy GP The American Cancer Society National Prostate Cancer Detection Project Findings on the detection of early prostate cancer in 2425 men Cancer 1991 67 2949 2958 Lee F McHugh TA Solomon MH Dorr RP Siders DB Kirscht JL Christensen LL Mitchell A Transrectal ultrasound digital rectal examination and prostate specific antigen Preliminary results of an early detection program for prostate cancer Scand J Urol Nephrol 1991 137 Suppl 101 105 Catalona WJ Richie JP Ahmann FR Hudson MA Scardino PT Flanigan RC deKernion JB Ratliff TL Kavoussi LR Dalkin BL Waters WB MacFarlane MT Southwick PC Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer Results of a multicenter clinical trial of 6 630 men J Urol 1994 151 1283 1290 Stamey TA
20. Yang N Hay AR McNeal JE Freiha FS Redwine E Prostate specific antigen as a serum marker for adenocarcinoma of the prostate New Engl J Med 1987 317 909 916 Stamey TA Kabalin JN Prostate specific antigen in the diagnosis and treatment o adenocarcinoma of the prostate I Untreated patients J Urol 1989 141 1070 1075 Killian CS Yang N Emrich LJ Vargas FP Kuriyama M Wang MC Slack NH Papsidero LD Murphy GP Chu TM Prognostic importance of prostate specific antigen for monitoring patients with stages B2 to D1 prostate cancer Cancer Res 1985 45 886 891 Stamey TA Kabalin JN McNeal JE Johnstone IM Freiha FS Redwine E Yang N Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate Il Radical prostatectomy treated patients J Urol 1989 141 1076 1083 Stamey TA Kabalin JN Ferrari M Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate Ill Radiation treated patients J Urol 1989 141 1084 1087 Stamey TA Kabalin JN Ferrari M Yang N Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate IV Anti androgen treated patients J Urol 1989 141 1088 1090 Schacht MJ Garnett JE Grayhack JT Biochemical markers in prostatic cancer Urol Clin No Amer 1984 11 253 267 Wang MC Valenzuela LA Murphy GP Chu TM Purification of a human prostate specific antigen Invest Urol 1979 17 159 163 Lilja H Structure f
21. ement QC amp QA ASOP Press Chicago IL 1989 Kricka L Interferences in Immunoassays Still a Threat Clin Chem 2000 46 1037 1038 Bjerner J et al Immunometric Assay Interference Incidence and Prevention Clin Chem 2002 48 613 621 Approved Guideline Protocols for determination of limits of detection and limits of quantitation EP17 A October 2004 Clinical and Laboratory Standards Institute HHS Publication 4th ed April 1999 Biosafety in Microbiological and Biomedical Laboratories Available http www cdc gov od ohs biosfty bmbl4 bmbl4toc htm IFU_2010_A85067B 7135 0063 5 7 TOC TEL 0120 566 730 FAX 03 5530 2460 7135 0063 5 7 TOC 37200_1311
22. patients Cancer Res 1980 40 2428 2432 Stamey TA Teplow DB Graves HC Identity of PSA purified from seminal fluid by different methods comparison by amino acid analysis and assigned extinction coefficients Prostate 1995 27 198 203 Carter HB Pearson JD Metter EJ et al Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease JAMA 1992 267 2215 20 Carter HB Ferrucci L Kettermann A et al Detection of life threating prostate cancer with prostate specific antigen velocity during a window of curabliity J Natl Cancer Inst 2006 98 1521 7 Punglia RS D Amico AV Catalona WJ et al Effect of verification bias on screening for prostate cancer by measurement of prostate specific antigen N Eng J Med 2003 349 335 342 Catalona WJ Smith BS Ornstein DK Prostate cancer detection in men with serum PSA concentrations of 2 6 to 4 0 ng mL and benign prostatic examination Enhancement of specificity with free PSA measurements JAMA 1997 277 1452 1455 Babaian RJ Johnston DA Naccarato W et al The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2 5 and 4 0 ng mL Relationship to biopsy strategy J Urol 2001 165 757 760 Armitage TG Cooper EH Newling DW Robinson MR Appleyard I The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer Br J Urol 1988 Dec 62
23. unction and regulation of the enzyme activity of prostate specific antigen World J Urol 1993 11 188 191 Lilja H Christensson A Dahlen V et al Prostate specific antigen in human serum occurs predominately in complex with alpha 1 antichymotrypsin Clin Chem 1991 37 1618 1625 Graves HC Standardization of immunoassays for prostate specific antigen Cancer 1993 72 3141 3144 Graves HC Issues on standardization of immunoassays for prostate specific antigen Clin Invest Med 1993 16 415 424 McCormack RT Rittenhouse HG Finlay JA Sokoloff RL Wang TJ Wolfert RL Lilja H Oesterling JE Molecular forms of prostate specific antigen and the human kallikrein gene family A new era Urology 1995 45 729 744 Nadji M Tabei SZ Castro A Chu TA Murphy GP Wang MC Morales AR Prostate Specific antigen An immunological marker for prostate neoplasms Cancer 1981 48 1229 1232 3 3 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 Wang MC Papsidero LD Kuriyama M Valenzuela LA Murphy GP Chu TM Prostatic antigen A new potential marker for prostatic cancer Prostate 1981 2 89 96 Frankel AE Rouse RV Wang MC Chu TM Herzenberg LA Monoclonal antibodies to a human prostate antigen Cancer Res 1982 42 3714 3717 Papsidero LD Wang MC Valenzuela LA Murphy GP Chu TM A prostate antigen in sera of prostatic cancer
Download Pdf Manuals
Related Search